Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

The use of 90 mg/m<sup>2</sup> daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m<sup>2</sup> once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-09-16
DOI
https://doi.org/10.1200/jco.24.00235
Citations
14
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
6.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

Johannes Schetelig, Christian Thiede, Michael Krämer, Markus Schaich et al.
14 citations
Journal of Clinical Oncology
Acute Myeloid Leukemia Research
6.36
article

Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

Johannes Schetelig, Christian Thiede, Michael Krämer, Markus Schaich, Sabine Käyser, Sebastian Scholl, Wolfgang E. Berdel, Björn Steffen, Christoph Röllig, Martin Bornhäuser, Carsten Müller‐Tidow, Claudia Dorothea Baldus, Andreas Hochhaus, Jan Moritz Middeke, Dirk Niemann, Jan Novák, Annett Haake, Andreas Neubauer, Friedrich Stölzel, Edgar Jost, Regina Herbst, Christoph Schmid, Jiřı́ Mayer, Barbora Weinbergerová, Frank Fiebig, Andreas Rank, Jolana Mertová, Mathias Hänel, Nael Alakel, Tomáš Szotkowski, Lars R. Fransecky, Jan-Henrik Mikesch, Christoph Schliemann, Andreas Burchert, Maher Hanoun, Uwe Platzbecker, Stefan W. Krause, Richard Noppeney, Hubert Serve, Tim Sauer, Martin Kaufmann, G. Ehninger, Gerhard Held, Kerstin Schäfer‐Eckart
article en
14 citations

Abstract

The use of 90 mg/m<sup>2</sup> daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m<sup>2</sup> once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.

Journal of Clinical OncologyVol. 43(1)
Goethe University Frankfurt (DE), Philipps University of Marburg (DE), German Cancer Research Center (DE), Charles University (CZ), Heidelberg University (DE), University Hospital Augsburg (DE), University Hospital Heidelberg (DE), Robert Bosch Hospital (DE), Universitätsklinikum Erlangen (DE), Westpfalz Klinikum (DE), Rems-Murr-Klinikum (DE), Institute of Haematology and Blood Transfusion (CZ), Nuremberg Hospital (DE), University Hospital Brno (CZ), University Hospital Münster (DE), National Center for Tumor Diseases (DE), University Hospital Schleswig-Holstein (DE), Universitätsklinikum Aachen (DE), University Hospital Leipzig (DE), University Hospital Frankfurt (DE), Jena University Hospital (DE), Gemeinschaftsklinikum Mittelrhein (DE), University Hospital Kralovske Vinohrady (CZ), University Medical Centre Mannheim (DE), Klinikum Chemnitz (DE), University of Duisburg-Essen (DE), Palacký University Olomouc (CZ), Technische Universität Dresden (DE), RWTH Aachen University (DE), University of Lübeck (DE)
Good health and well-being
Openalex Percentile: Top 3%
Acute Myeloid Leukemia Research
6.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.